

AMENDED CLAIM SET:

1. (Previously Presented) A peptide comprising a portion of an endostatin protein, wherein said peptide is of length from 7-20 amino acids long and contains a pair of proline residues at least one of which is a terminal residue or a residue penultimate to a terminus of the peptide, and wherein said peptide exhibits an IC_{50} of 20 μ M or less in a bovine aorta endothelial cell proliferation assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 30% at a dose of 50 μ g/coverslip.

2. (Original) The peptide of claim 1 that exhibits an IC_{50} of 20 nM to 20 mM in a bovine aorta endothelial cell assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 50% at a dose of 10 to 25 μ g/coverslip.

3. - 5. (Cancelled)

6. (Original) The peptide of claim 1 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

7. (Previously Presented) The peptide of claim 1 that has a length of 9 to 20 amino acids.

8. (Original) The peptide of claim 7 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.

9. (Cancelled)

10. (Withdrawn) The peptide of claim 1, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 29-32.

11. (Cancelled)

12. (Cancelled)

13. (Original) A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.

14. (Original) The composition according to claim 13, wherein said composition provides a unit dose of from 20 $\mu\text{g/kg/day}$ to 2 mg/kg/day .

15. (Withdrawn) A pharmaceutical composition comprising a peptide according to claim 10 and a pharmaceutically acceptable carrier.

16. (Withdrawn) The composition according to claim 15, wherein said composition provides a unit dose of from 20 $\mu\text{g/kg/day}$ to 2 mg/kg/day.

17. (Cancelled)

18. (Cancelled)

19. (Previously Presented) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 13 to a subject.

20. (Withdrawn) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 15 to a subject.

21. (Cancelled)

22. (Currently Amended) A method for preventing or treating primary tumor growth or metastasis by ~~preventing or~~ inhibiting tumor angiogenesis, said method comprising administering to a subject ~~at risk for or~~ presenting a tumor an effective amount of the composition of claim 13.

23. (Withdrawn/Currently Amended) A method for preventing or treating primary tumor growth or metastasis by ~~preventing or~~ inhibiting tumor angiogenesis, said method comprising administering the composition of claim 15 to a subject ~~at risk for or~~ presenting a tumor.

24. (Cancelled)

25. (Previously Presented) The peptide of claim 1, comprising the peptide having the amino acid sequence of SEQ ID NO:30.

26. (Previously Presented) A pharmaceutical composition comprising the peptide according to claim 25 and a pharmaceutically acceptable carrier.

27. (Previously Presented) A method for inhibiting angiogenesis in a tumor comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 26 to a subject.

28. (Currently Amended) A method for preventing or treating primary tumor growth or metastasis by ~~preventing or~~ inhibiting tumor angiogenesis, said method comprising administering to a subject ~~at risk for or~~ presenting a tumor an effective amount of the composition of claim 26.

29. (Previously Presented) The peptide of claim 1, having two proline residues each being located penultimate to a terminus of the peptide.